PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Lu KH, Broaddus RR, Longo DL. Endometrial cancer. N Engl J Med. 2020;383(21):2053–2064. doi:10.1056/NEJMra151401033207095
   PubMed Web of Science ®Google Scholar
• Del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127(3):651–661. doi:10.1016/j.ygyno.2012.09.01223000148
   PubMed Web of Science ®Google Scholar
• World Health Organization. Classification of Tumours: Female Genital Tumours. 5th ed. Lyon (France): International Agency for Research on Cancer; 2020.
   Google Scholar
• Zhang L, Kwan SY, Wong KK, Solaman PT, Lu KH, Mok SC. Pathogenesis and clinical management of uterine serous carcinoma. Cancers. 2020;12(3):686. doi:10.3390/cancers12030686
   PubMed Web of Science ®Google Scholar
• Schwab CL, Santin AD. Targeted therapy in the treatment of uterine serous carcinoma. Pharmacogenomics. 2015;16(2):97–99. doi:10.2217/pgs.14.17625616096
   PubMed Web of Science ®Google Scholar
• Heim D, Budczies J, Stenzinger A, et al. Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. Int J Cancer. 2014;135(10):2362–2369. doi:10.1002/ijc.2888224706491
   PubMed Web of Science ®Google Scholar
• Hoadley KA, Yau C, Wolf DM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014;158(4):929–944. doi:10.1016/j.cell.2014.06.04925109877
   PubMed Web of Science ®Google Scholar
• Zhong H, Chen H, Qiu H, Huang C, Wu Z. A multiomics comparison between endometrial cancer and serous ovarian cancer. PeerJ. 2020;8e8347. doi:10.7717/peerj.8347
   Web of Science ®Google Scholar
• Matulonis UA, Shapira-Frommer R, Santin AD, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the Phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–1087. doi:10.1093/annonc/mdz13531046082
   PubMed Web of Science ®Google Scholar
• Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18(3):153–167. doi:10.1038/nri.2017.10828990585
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 Checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.01429562194
   PubMed Web of Science ®Google Scholar
• Sungu N, Yildirim M, Desdicioglu R, et al. Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer. Int J Gynecol Pathol. 2019;38(5):404–413. doi:10.1097/PGP.000000000000054330134343
   PubMed Web of Science ®Google Scholar
• Kucukgoz Gulec U, Kilic Bagir E, Paydas S, Guzel AB, Gumurdulu D, Vardar MA. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expressions in type 2 endometrial cancer. Arch Gynecol Obstet. 2019;300(2):377–382. doi:10.1007/s00404-019-05180-231076855
   PubMed Web of Science ®Google Scholar
• Kim J, Kim S, Lee HS, et al. Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecol Oncol. 2018;149(2):381–387. doi:10.1016/j.ygyno.2018.02.01329572029
   PubMed Web of Science ®Google Scholar
• Pasanen A, Ahvenainen T, Pellinen T, Vahteristo P, Loukovaara M, Butzow R. PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups. Am J Surg Pathol. 2020;44(2):174–181. doi:10.1097/PAS.000000000000139531651527
   PubMed Web of Science ®Google Scholar
• Sloan EA, Ring KL, Willis BC, Modesitt SC, Mills AM. PD-L1 expression in mismatch repair-deficient endometrial carcinomas, including lynch syndrome-associated and MLH1 promoter hypermethylated tumors. Am J Surg Pathol. 2017;41(3):326–333. doi:10.1097/PAS.000000000000078327984238
   PubMed Web of Science ®Google Scholar
• Li Z, Joehlin-Price AS, Rhoades J, et al. Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency. Int J Gynecol Cancer. 2018;28(1):59–68. doi:10.1097/IGC.000000000000112029053481
   PubMed Web of Science ®Google Scholar
• Talhouk A, Derocher H, Schmidt P, et al. Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 2019;25(8):2537–2548. doi:10.1158/1078-0432.CCR-18-324130523022
   PubMed Web of Science ®Google Scholar
• Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, Phase 2 trial. Lancet Oncol. 2019;20(5):711–718. doi:10.1016/s1470-2045(19)30020-830922731
   PubMed Web of Science ®Google Scholar
• Chen H, Molberg K, Strickland AL, et al. PD-L1 expression and CD8+ tumor-infiltrating lymphocytes in different types of tubo-ovarian carcinoma and their prognostic value in high-grade serous carcinoma. Am J Surg Pathol. 2020;44(8):1050–1060. doi:10.1097/PAS.000000000000150332384321
   PubMed Web of Science ®Google Scholar
• Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278. doi:10.1186/s40425-019-0768-931655605
   PubMed Web of Science ®Google Scholar
• Pham T, Roth S, Kong J, et al. An update on immunotherapy for solid tumors: a review. Ann Surg Oncol. 2018;25(11):3404–3412. doi:10.1245/s10434-018-6658-430039324
   PubMed Web of Science ®Google Scholar
• Liao JB. Immunotherapy for gynecologic cancers. Gynecol Oncol. 2016;142(1):3–5. doi:10.1016/j.ygyno.2016.05.02927242186
   PubMed Web of Science ®Google Scholar
• Schepisi G, Casadei C, Toma I, et al. Immunotherapy and its development for gynecological (ovarian, endometrial and cervical) tumors: from immune checkpoint inhibitors to chimeric antigen receptor (CAR)-T cell therapy. Cancers. 2021;13(4):840. doi:10.3390/cancers1304084033671294
   PubMed Web of Science ®Google Scholar
• Olawaiye AB, Rauh-Hain JA, Withiam-Leitch M, Rueda B, Goodman A, Del Carmen MG. Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma. Gynecol Oncol. 2008;110(3):293–298. doi:10.1016/j.ygyno.2008.05.02718644620
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol. 2003;91(3):463–469. doi:10.1016/j.ygyno.2003.08.01814675663
   PubMed Web of Science ®Google Scholar
• Van Der Putten LJ, Hoskins P, Tinker A, Lim P, Aquino-Parsons C, Kwon JS. Population-based treatment and outcomes of Stage I uterine serous carcinoma. Gynecol Oncol. 2014;132(1):61–64. doi:10.1016/j.ygyno.2013.11.00224219983
   PubMed Web of Science ®Google Scholar
• Solmaz U, Mat E, Ekin A, et al. Optimal cytoreduction, depth of myometrial invasion, and age are independent prognostic factors for survival in women with uterine papillary serous and clear cell carcinomas. Int J Surg. 2016:3271–3377. doi:10.1016/j.ijsu.2016.06.041
   Web of Science ®Google Scholar
• Mattes MD, Lee JC, Metzger DJ, Ashamalla H, Katsoulakis E. The incidence of pelvic and para-aortic lymph node metastasis in uterine papillary serous and clear cell carcinoma according to the SEER registry. J Gynecol Oncol. 2015;26(1):19–24. doi:10.3802/jgo.2015.26.1.1925310855
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu M, Yang JX, Cao DY, Shen K, Lang JH. Clinicopathological and survival analysis of uterine papillary serous carcinoma: a single institutional review of 106 cases. Cancer Manag Res. 2018;104915–104928. doi:10.2147/CMAR.S179566
   Web of Science ®Google Scholar
• Karalok A, Turan T, Basaran D, et al. Lymph node metastasis in patients with endometrioid endometrial cancer: overtreatment is the main issue. Int J Gynecol Cancer. 2017;27(4):748–753. doi:10.1097/IGC.000000000000093728301338
   PubMed Web of Science ®Google Scholar
• Lee J, Kong TW, Paek J, Chang SJ, Ryu HS. Predicting model of lymph node metastasis using preoperative tumor grade, transvaginal ultrasound, and serum CA-125 level in patients with endometrial cancer. Int J Gynecol Cancer. 2016;26(9):1630–1635. doi:10.1097/IGC.000000000000082027654258
   PubMed Web of Science ®Google Scholar
• Mahdi H, Elshaikh MA, Debenardo R, et al. Impact of adjuvant chemotherapy and pelvic radiation on pattern of recurrence and outcome in stage I non-invasive uterine papillary serous carcinoma. A multi-institution study. Gynecol Oncol. 2015;137(2):239–244. doi:10.1016/j.ygyno.2015.01.54425641568
   PubMed Web of Science ®Google Scholar
• Winer I, Ahmed QF, Mert I, et al. Significance of lymphovascular space invasion in uterine serous carcinoma. Int J Gynecol Pathol. 2015;34(1):47–56. doi:10.1097/pgp.000000000000011325473753
   PubMed Web of Science ®Google Scholar
• Solmaz U, Ekin A, Mat E, et al. Analysis of clinical and pathological characteristics, treatment methods, survival, and prognosis of uterine papillary serous carcinoma. Tumori. 2016;102(6):593–599. doi:10.5301/tj.500053127514313
   PubMed Web of Science ®Google Scholar
• Garg G, Gao F, Wright JD, Hagemann AR, Mutch DG, Powell MA. Positive peritoneal cytology is an independent risk-factor in early stage endometrial cancer. Gynecol Oncol. 2013;128(1):77–82. doi:10.1016/j.ygyno.2012.09.02623032094
   PubMed Web of Science ®Google Scholar
• Bristow RE, Duska LR, Montz FJ. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol. 2001;81(1):92–99. doi:10.1006/gyno.2000.611011277657
   PubMed Web of Science ®Google Scholar
• Patsavas K, Woessner J, Gielda B, et al. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol Oncol. 2011;121(3):581–585. doi:10.1016/j.ygyno.2010.11.04821440290
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol. 2007;107(2):190–193. doi:10.1016/j.ygyno.2007.05.03917825394
   PubMed Web of Science ®Google Scholar
• Kandoth C, Schultz N, Cherniack AD, et al.; Cancer Genome Atlas Research N. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. doi:10.1038/nature1211323636398
   PubMed Web of Science ®Google Scholar
• Talhouk A, Mcconechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 2015;113(2):299–310. doi:10.1038/bjc.2015.19026172027
   PubMed Web of Science ®Google Scholar